Veradermics (MANE) Net Cash Flow (2025 - 2026)
Veradermics' (MANE) quarterly Net Cash Flow came in at $146.6 million in Q1 2026, up 810.79% YoY from $16.1 million in Q1 2025, and up 810.79% on a QoQ basis from -$20.6 million in Q1 2025.
Powered by 
Analysis
Veradermics (MANE) Net Cash Flow (2025 - 2026) Analysis & Trends
Veradermics (MANE) has 2 years of Net Cash Flow data on file, last reported at $146.6 million in Q1 2026.
- Quarterly Net Cash Flow rose 810.79% year-over-year to $146.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $126.0 million (changed N/A YoY) and the FY2025 annual result came in at -$31.3 million, down 185.13% from the prior year.
- Net Cash Flow rose to $146.6 million in Q1 2026, from -$20.6 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $146.6 million in Q1 2026 to a low of -$20.6 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Veradermics | 3.96 Bn | 3.96 Bn | - | 150.91 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 150.91 Mn |
| Mar 31, 2026 | 146.61 Mn |
| Jun 30, 2025 | -23.88 Mn |
| Mar 31, 2025 | -20.64 Mn |